Printer Friendly

ANDRX LICENSES SUSTAINED RELEASE PRODUCT TO ZENITH LABORATORIES

 FORT LAUDERDALE, Fla., Oct. 19 /PRNewswire/ -- Andrx Corporation announced today that its wholly owned subsidiary AndaSR Pharmaceuticals, Inc. has signed an agreement with Zenith Laboratories, Inc. (NASDAQ: ZENL) for the development and licensing of a generic version of a sustained release product used in the treatment of a variety of cardiovascular conditions. The terms of the agreement have not been disclosed. The product, which will be manufactured by Zenith, utilizes patent pending technology developed by Chih Ming Chen, Ph.D., president of AndaSR.
 Elliot F. Hahn Ph.D., president of Andrx, stated: "We are very pleased to enter into an agreement with Zenith which is considered one of the leading generic pharmaceutical companies. Their science, manufacturing, and extremely strong sales and marketing group will make an excellent partner for us. This agreement is consistent with Andrx' strategy of selectively licensing a portion of the 12 sustained release drugs currently under development by AndaSR."
 Andrx is a pharmaceutical holding company consisting of three operating divisions: Anda Generics, a generic distribution company, AndaSR Pharmaceuticals, a developer and manufacturer of controlled- release generic products and Aura Labs, an ethical pharmaceutical company.
 -0- 10/19/93
 /CONTACT: Elliot F. Hahn, Ph.D., president, Andrx Corporation, 305-584-0300/
 (ZENL)


CO: Andrx Corporation; Zenith Laboratories, Inc. ST: Florida IN: MTC SU: LIC

AW-SS -- FL031 -- 4241 10/19/93 17:35 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 19, 1993
Words:224
Previous Article:MIDWEST POWER SYSTEMS DECLARES DIVIDEND
Next Article:CIATTI'S REPORTS FIRST QUARTER, FISCAL 1994 RESULTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters